

AMENDMENT TO _____
OFFERED BY MR. PAUL OF TEXAS

At the end of part 1 of subtitle C of title V of division C, insert the following:

1 **SEC. 2574. CLAIMS ABOUT THE EFFECTS OF FOOD AND DIETARY SUPPLEMENTS.**
2

3 (a) **LIMITATION ON SUPPRESSION BY FEDERAL GOVERNMENT OF CLAIMS IN FOOD AND DIETARY SUPPLEMENTS.**—The Federal Government may not take any action to prevent use of a claim describing any nutrient in a food or dietary supplement (as such terms are defined in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321)) as mitigating, treating, or preventing any disease, disease symptom, or health-related condition, unless in a final order of a Federal court following a trial on the merits finds clear and convincing evidence based on qualified expert opinion and published peer-reviewed scientific research that—

15 (1) the claim is false and misleading in any material respect; and

17 (2) there is no less speech restrictive alternative to claim suppression, such as use of disclaimers or

1 qualifications, that can render the claim non-mis-
2 leading.

3 (b) HEALTH INFORMATION.—Section 5 of the Fed-
4 eral Trade Commission Act (15 U.S.C. 45) is amended
5 by adding at the end the following:

6 “(o) ADVERTISING OF DIETARY SUPPLEMENTS AND
7 DIETARY INGREDIENTS.—

8 “(1) DEFINITIONS.—In this subsection—

9 “(A) the term ‘dietary supplement’ has the
10 meaning given to that term in section 201(ff)
11 (21 U.S.C. 321(ff)) of the Federal Food, Drug,
12 and Cosmetic Act; and

13 “(B) the term ‘dietary ingredient’ means
14 an ingredient listed in subparagraph (A)
15 through (F) of section 201(ff)(1) (21 U.S.C.
16 321(ff)(1)) of the Federal Food, Drug, and
17 Cosmetic Act that is included in, or that is in-
18 tended to be included in, a dietary supplement.

19 “(2) EXEMPTIONS FROM REGULATION AS AD-
20 VERTISING.—No content of any publication shall be
21 considered advertising regulable under this Act un-
22 less the content is intended by the seller of a prod-
23 uct to promote the sale of that product and the con-
24 tent includes (A) the name of the product offered for
25 sale; (B) an express offer to sell the named product;

1 and (C) a purchase price for the product. No con-
2 tent excerpted in whole or part from a peer-reviewed
3 scientific publication shall be considered advertising
4 regulable under this Act.

5 “(3) NO IMPLIED CLAIMS.—In any investiga-
6 tion commenced by the Commission and in any adju-
7 dicative proceeding in which the Commission is a
8 party, the Commission shall not attribute to an ad-
9 vertiser accused of false advertisement any adver-
10 tising statement not actually made by that adver-
11 tiser.

12 “(4) NOTICE, OPPORTUNITY TO CURE, AND
13 BURDEN OF PROOF FOR INVESTIGATION.—Before
14 the Commission authorizes an investigation of false
15 advertisement by an advertiser of a dietary supple-
16 ment or a dietary ingredient, the Commission shall
17 send the advertiser a written ‘Notice of Suspected
18 Violation and Opportunity to Cure’ informing the
19 advertiser of—

20 “(A) the precise advertising statement that
21 the Commission suspects may be false or mis-
22 leading;

23 “(B) the scientific basis for the Commis-
24 sion’s view that any statement of health benefit
25 may be false or misleading; and

1 “(C) a date certain, not less than 30 days
2 after the date of the advertiser’s receipt of the
3 notice, by which the advertiser may voluntarily
4 discontinue further use of the statement the
5 Commission suspects may be false or mis-
6 leading and, upon so doing, the advertiser shall
7 not be subject to an investigation of false adver-
8 tisement by the Commission for the statement.

9 The Commission shall not commence any investiga-
10 tion of an advertiser of a dietary supplement or a di-
11 etary ingredient to determine whether the advertiser
12 has disseminated a false advertisement unless it pos-
13 sesses before the commencement of such investiga-
14 tion clear and convincing evidence that the advertise-
15 ment is false and misleading.

16 “(5) BURDEN OF PROOF FOR FALSE ADVER-
17 TISEMENT CASES.—In every proceeding before a
18 court or the Commission in which an advertiser of
19 a dietary supplement or a dietary ingredient is
20 charged with false advertising, the burden of proof
21 shall be on the Commission to establish by clear and
22 convincing evidence that the advertisement is false,
23 that the advertisement actually caused consumers to
24 be misled into believing to be true that which is
25 false, and that but for the false advertising content

1 the consumer would not have made the purchase at
2 the price paid. If a claimed health benefit of a die-
3 tary supplement or dietary ingredient is alleged to
4 be false advertising, the Commission must addition-
5 ally establish based on expert scientific opinion and
6 published peer-reviewed scientific evidence that the
7 claim is false. No order adverse to the advertiser
8 shall be entered except upon the Commission satis-
9 fying this burden of proof.”

10 (c) DEFINITION OF DRUG.—

11 (1) IN GENERAL.—Subparagraph (1) of section
12 201(g) of the Federal Food, Drug, and Cosmetic Act
13 (21 U.S.C. 321(g)) is amended by striking the sec-
14 ond and third sentences and inserting the following:
15 “A food or dietary supplement for which a claim is
16 made in accordance with section 403(r)(1)(B) is not
17 a drug solely because of such claim.”

18 (2) RULES.—All rules of the Food and Drug
19 Administration in existence on the date of the enact-
20 ment of this Act prohibiting nutrient-disease rela-
21 tionship claims are revoked.

22 (d) MISBRANDED FOOD.—Section 403(r) of the Fed-
23 eral Food, Drug, and Cosmetic Act (21 U.S.C. 343(r))
24 is amended—

1 (1) by striking clause (B) of subparagraph (1)
2 and inserting the following:

3 “(B) describes any nutrient as mitigating,
4 treating, or preventing any disease, disease
5 symptom, or health-related condition if, and
6 only if, the claim has been adjudicated false and
7 misleading in any material respect by final
8 order of a Federal court of competent jurisdic-
9 tion in accordance with section 2 of the Health
10 Freedom Protection Act.”;

11 (2) by striking subparagraph (3);

12 (3) in the first sentence of subparagraph

13 (4)(A)(i)—

14 (A) by striking “or (3)(B)”; and

15 (B) by striking “or (1)(B)”;

16 (4) by striking clause (C) of subparagraph (4);

17 (5) by striking clause (D) of subparagraph (5);

18 and

19 (6) in subparagraph (6), by striking the second

20 sentence.

21 (e) DIETARY SUPPLEMENT LABELING EXEMP-
22 TIONS.—Section 403B of the Federal Food, Drug, and
23 Cosmetic Act (21 U.S.C. 343–2) is amended to read as
24 follows:

1 “FOOD AND DIETARY SUPPLEMENT LABELING

2 “SEC. 403B. The Federal Government shall take no
3 action to prevent distribution of any publication in connec-
4 tion with the sale of a food or dietary supplement to con-
5 sumers unless it establishes that a claim contained in the
6 publication—

7 “(1) names the specific food or dietary supple-
8 ment sold by the person causing the publication to
9 be distributed;

10 “(2) represents that the specific food or dietary
11 supplement mitigates, treats, or prevents a disease;
12 and

13 “(3) proves the claim to be false and misleading
14 in any material respect by final order of a Federal
15 court of competent jurisdiction in accordance with
16 section 2 of the Health Freedom Protection Act.”.

⊠